Summary
Global Markets Direct’s, ‘Novartis AG - Product Pipeline Review - 2016’, provides an overview of the Novartis AG’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG
- The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Novartis AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Novartis AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Novartis AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Novartis AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Novartis AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Novartis AG Snapshot 8
Novartis AG Overview 8
Key Information 8
Key Facts 8
Novartis AG - Research and Development Overview 9
Key Therapeutic Areas 9
Novartis AG - Pipeline Review 28
Pipeline Products by Stage of Development 28
Pipeline Products - Monotherapy 29
Pipeline Products - Combination Treatment Modalities 30
Pipeline Products - Partnered Products 31
Pipeline Products - Out-Licensed Products 34
Novartis AG - Pipeline Products Glance 36
Novartis AG - Late Stage Pipeline Products 36
Novartis AG - Clinical Stage Pipeline Products 40
Novartis AG - Early Stage Pipeline Products 49
Novartis AG - Drug Profiles 52
ceritinib 52
dabrafenib mesylate + trametinib dimethyl sulfoxide 55
eltrombopag olamine 57
everolimus 60
serelaxin 66
trametinib dimethyl sulfoxide 69
zoledronic acid 72
imatinib mesylate 74
panobinostat 77
pazopanib hydrochloride 84
(glycopyrrolate + indacaterol maleate + mometasone fuorate) 89
(indacaterol maleate + mometasone furoate) 90
(sacubitril + valsartan) 92
alpelisib 95
bimagrumab 97
buparlisib hydrochloride 99
canakinumab 103
dabrafenib mesylate 106
fevipiprant 109
fingolimod hydrochloride 111
midostaurin 114
nilotinib 116
ofatumumab 120
osilodrostat phosphate 125
oxytocin 127
pasireotide 129
pasireotide ER 132
ranibizumab 134
ribociclib 138
secukinumab 141
siponimod 147
CDZ-173 149
clofazimine 150
CNP-520 151
(dectrekumab + VAK-694) 152
afuresertib hydrochloride 153
aldesleukin 156
BHQ-880 158
BVS-857 160
capmatinib 161
CFZ-533 164
cipargamin 166
CJM-112 167
dectrekumab 168
EGF-816 170
elgemtumab 171
EMA-401 173
FCR-001 175
GSK-2285921 177
HSC-835 179
iloperidone 180
infigratinib 182
KAF-156 183
KRP-203 184
LCL-161 186
LFX-453 188
LHW-090 189
ligelizumab 190
LJN-452 192
LMI-070 193
mavoglurant 194
MCS-110 196
octreotide acetate long acting 197
pradigastat sodium 199
ruxolitinib phosphate 200
selurampanel 205
sonidegib phosphate 206
tesidolumab 210
tisagenlecleucel-T 212
trametinib dimethyl sulfoxide + uprosertib 215
uprosertib 217
VAY-736 218
BZF-961 220
CGF-166 221
CSJ-137 223
CSJ-148 224
FGF-401 225
HDM-201 226
LAG-525 227
lapatinib ditosylate 228
MGB-453 232
PDR-001 233
PIM-447 234
RAF-265 235
sotrastaurin acetate 236
ABL-001 238
AV-380 239
Cellular Immunotherapy to Target c-Met for Oncology 240
Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia 241
Cellular Immunotherapy to Target EGFR for Glioblastoma 242
CGM-097 243
CLR-325 244
huCART19 245
IDH-305 246
IMP-701 247
LEQ-506 248
LGK-974 249
LML-134 250
LNA-043 251
LXH-254 252
LXS-196 253
MesoCART 254
NOV-10 255
NOV-11 256
NOV-7 257
NOV-8 258
NOV-9 259
octreotide acetate LAR 260
PBF-509 261
PCA-062 263
QCC-374 264
CART-123 265
Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma 266
Antibody to Inhibit PD-L1 for Oncology 267
AUSRM-057 268
BLZ-945 269
BQS-481 271
BVB-808 272
Cellular Immunotherapy Program for Oncology 273
Cellular Immunotherapy to Target GD2 for Neuroblastoma 274
CHZ-868 275
cosyntropin ER 276
ESK-1 277
GNFPf-5069 278
Kartogenin 279
KR-22809 280
LCZ-960 281
LGB-321 282
LKZ-145 283
LQN-725 284
Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases 285
NIBR-0213 286
NITD-349 287
NITD-916 288
NVPQBE-170 289
NVPTNKS-656 290
OXB-302 291
RP-6503 292
Small Molecule to Agonize GPR119 for Type 2 Diabetes 293
Small Molecule to Agonize GPR39 for Type 2 Diabetes 294
Small Molecule to Agonize Nurr1 for Multiple Sclerosis 295
Small Molecule to Inhibit LRRK2 for Parkinson's Disease 296
Small Molecule to Inhibit OX2R for Insomnia 297
Small Molecules to Antagonize VEGFR2 for Solid Tumors 298
Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis 299
Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 300
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer 301
Small Molecules to Inhibit Pan-RAF Kinase for Oncology 302
Small Molecules to Inhibit Renin for Hypertension 303
XOMA-089 304
ESBA-903 SR 305
LJH-685 306
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology 307
Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD 308
Small Molecules for Tuberculosis 309
Small Molecules for Undisclosed Indication 310
Small Molecules to Antagonize NR2B for Depression 311
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 312
Small Molecules to Inhibit CFTR for Secretory Diarrhea 313
Small Molecules to Inhibit FPPS for Soft Tissue Cancer 314
Small Molecules to Inhibit PfATP4 for Malaria 315
Small Molecules to Inhibit PI4KIIIbeta for HCV 316
Novartis AG - Pipeline Analysis 317
Novartis AG - Pipeline Products by Target 317
Novartis AG - Pipeline Products by Route of Administration 330
Novartis AG - Pipeline Products by Molecule Type 331
Novartis AG - Pipeline Products by Mechanism of Action 332
Novartis AG - Recent Pipeline Updates 342
Novartis AG - Dormant Projects 436
Novartis AG - Discontinued Pipeline Products 443
Novartis AG - Discontinued Pipeline Products 443
Discontinued Pipeline Product Profiles 445
Novartis AG - Company Statement 457
Novartis AG - Locations And Subsidiaries 458
Head Office 458
Other Locations & Subsidiaries 458
Appendix 475
Methodology 475
Coverage 475
Secondary Research 475
Primary Research 475
Expert Panel Validation 475
Contact Us 475
Disclaimer 476
List of Tables
Novartis AG, Key Information 21
Novartis AG, Key Facts 21
Novartis AG - Pipeline by Indication, 2016 23
Novartis AG - Pipeline by Stage of Development, 2016 41
Novartis AG - Monotherapy Products in Pipeline, 2016 42
Novartis AG - Combination Treatment Modalities in Pipeline, 2016 43
Novartis AG - Partnered Products in Pipeline, 2016 44
Novartis AG - Partnered Products/ Combination Treatment Modalities, 2016 45
Novartis AG - Out-Licensed Products in Pipeline, 2016 47
Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 48
Novartis AG - Pre-Registration, 2016 49
Novartis AG - Filing rejected/Withdrawn, 2016 50
Novartis AG - Phase III, 2016 51
Novartis AG - Phase II, 2016 53
Novartis AG - Phase I, 2016 57
Novartis AG - Phase 0, 2016 61
Novartis AG - Preclinical, 2016 62
Novartis AG - Discovery, 2016 64
Novartis AG - Pipeline by Target, 2016 330
Novartis AG - Pipeline by Route of Administration, 2016 343
Novartis AG - Pipeline by Molecule Type, 2016 344
Novartis AG - Pipeline Products by Mechanism of Action, 2016 345
Novartis AG - Recent Pipeline Updates, 2016 355
Novartis AG - Dormant Developmental Projects,2016 449
Novartis AG - Discontinued Pipeline Products, 2016 456
Novartis AG, Subsidiaries 471
List of Figures
Novartis AG - Pipeline by Top 10 Indication, 2016 23
Novartis AG - Pipeline by Stage of Development, 2016 41
Novartis AG - Monotherapy Products in Pipeline, 2016 42
Novartis AG - Combination Treatment Modalities in Pipeline, 2016 43
Novartis AG - Partnered Products in Pipeline, 2016 44
Novartis AG - Out-Licensed Products in Pipeline, 2016 47
Novartis AG - Pipeline by Top 10 Target, 2016 330
Novartis AG - Pipeline by Top 10 Route of Administration, 2016 343
Novartis AG - Pipeline by Top 10 Molecule Type, 2016 344
Novartis AG - Pipeline Products by Top 10 Mechanism of Action, 2016 345
